يعرض 1 - 2 نتائج من 2 نتيجة بحث عن '"sequence copy number"', وقت الاستعلام: 0.31s تنقيح النتائج
  1. 1
    Academic Journal

    المساهمون: Cell cultures were provided by the CUC «Vertebrate Cell Culture Collection». The research was supported by the Ministry of Education and Science of the Russian Federation, Agreement № 075‑15‑2021‑683., Клеточные культуры предоставлены ЦКП «Коллекция культур клеток позвоночных». Работа выполнена при финансовой поддержке гранта Минобрнауки Российской Федерации, Соглашение № 075‑15‑2021‑683.

    المصدر: Measurement Standards. Reference Materials; Том 19, № 2 (2023); 5-17 ; Эталоны. Стандартные образцы; Том 19, № 2 (2023); 5-17 ; 2687-0886

    وصف الملف: application/pdf

    Relation: https://www.rmjournal.ru/jour/article/view/384/279; Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries / H. Sung [et al.] // CA: A Cancer Journal for Clinicians. 2021. Vol. 71, № 3. P. 209–249. https://doi.org/10.3322/caac.21660; Loeb K. R., Loeb L. A. Significance of multiple mutations in cancer // Carcinogenesis. 2000. Vol. 21, № 3. P. 379–385. https://doi.org/10.1093/carcin/21.3.379; Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers / K. B. Kuchenbaecker [et al.] // JAMA. 2017. Vol. 317, № 23. P. 2402–2416. https://doi:10.1001/jama.2017.7112; Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies / A. Antoniou [et al.] // American Journal of Human Genetics. 2003. Vol. 72, № 5. P. 1117–1130. https://doi:10.1086/375033; Chen S., Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance // Journal of Clinical Oncology. 2007. Vol. 25, № 11. P. 1329–1333. https://doi:10.1200/JCO.2006.09.1066; Cancer risks associated with BRCA1 and BRCA2 pathogenic variants / S. Li [et al.] // Journal of Clinical Oncology. 2022. Vol. 40, № 14. P. 1529–1541. https://doi.org/10.1200/JCO.21.02112; Berger M. F., Mardis E. R. The emerging clinical relevance of genomics in cancer medicine // Nature Reviews Clinical Oncology. 2018. Vol. 15, № 6. P. 353–365. https://doi.org/10.1038/s41571-018-0002-6; Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment / K. Haratani [et al.] // Annals of Oncology. 2017. Vol. 28, № 7. P. 1532–1539. https://doi.org/10.1093/annonc/mdx183; Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer / E. V. Cutsem [et al.] // Journal of Clinical Oncology. 2015. Vol. 33, № 7. P. 692–700. https://doi.org/10.1200/JCO.2014.59.4812; Development of NIST standard reference material 2373: Genomic DNA standards for HER2 measurements / Hua-Jun He [et al.] // Biomolecular Detection and Quantification. 2016. Vol. 8. P. 1–8. https://doi.org/10.1016/j.bdq.2016.02.001; Development and interlaboratory evaluation of a NIST reference material RM 8366 for EGFR and MET gene copy number measurements / H. J. He [et al.] // Clinical Chemistry and Laboratory Medicine. 2019. Vol. 57, № 8. P. 1142–1152. https://doi.org/10.1515/cclm-2018–1306; Metrological framework to support accurate, reliable, and reproducible nucleic acid measurements / M. Milavec [et al.] // Analytical and Bioanalytical Chemistry. 2022. Vol. 414, № 2. P. 791–806. https://doi.org/10.1007/s00216–021–03712-x; Alkabban F. M., Ferguson T. Breast cancer. Treasure Island: StatPearls Publishing, 2022. URL: https://www.ncbi.nlm.nih.gov/books/NBK482286 (дата обращения: 08.11.2022).; Activating HER2 mutations in HER2 gene amplification negative breast cancer / R. Bose [et al.] // Cancer Discov. 2013. Vol. 3, № 2. P. 224–237. https://doi.org/10.1158/2159–8290.CD-12–0349; Iqbal N., Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications // Molecular Biology International. 2014. № 852748. https://doi:10.1155/2014/852748; Moasser M. M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis // Oncogene. 2007. Vol. 26, № 45. P. 6469–6487. https://doi:10.1038/sj.onc.1210477; Centromere 17 copy number gain reflects chromosomal instability in breast cancer / K. Lee [et al.] // Scientific Reports. 2019. Vol. 9, № 1. P. 17968. https://doi.org/10.1038/s41598–019–54471-w; Scherer W. F., Syverton J. T., Gey, G. O. Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix // Journal of Experimental Medicine. 1953. Vol. 97, № 5. P. 695–710. https://doi:10.1084/jem.97.5.695; Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples / Y. Zhu [et al.] // Experimental and Molecular Pathology. 2015. Vol. 100, № 2. P. 287–293. https://doi:10.1016/j.yexmp.2015.11.027; Certification of standard reference material 2372a; Human DNA quantitation standard / E. L. Romsos [et al.] // NIST Special Publication. 2018. P. 260–189. https://doi:10.6028/NIST.SP.260–189; Use of the MLPA assay in the molecular diagnosis of gene copy number alterations in human genetic diseases / L. Stuppia [et al.] // International Journal of Molecular Sciences. 2012. Vol. 13, № 3. P. 3245–3276. https://doi:10.3390/ijms13033245; Cousineau I., Belmaaza A. EMSY overexpression disrupts the BRCA2/ RAD51 pathway in the DNA-damage response: Implications for chromosomal instability/recombination syndromes as checkpoint diseases // Molecular Genetics and Genomics. 2011. Vol. 285, № 4. P. 325–340. https://doi:10.1007/s00438-011-0612-5; https://www.rmjournal.ru/jour/article/view/384

  2. 2